{"id":403346,"date":"2020-12-21T03:53:33","date_gmt":"2020-12-21T08:53:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403346"},"modified":"2020-12-21T03:53:33","modified_gmt":"2020-12-21T08:53:33","slug":"avacta-group-plc-signs-license-agreement-with-astrea-bioseparations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/","title":{"rendered":"Avacta Group plc Signs License Agreement With Astrea Bioseparations"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Avacta Group plc Signs License Agreement With Astrea Bioseparations<\/b><\/p>\n<p class=\"bwalignc\"><i>License for the use of the Affimer platform for affinity purification applications<\/i><\/p>\n<p>CAMBRIDGE, England &amp; WETHERBY, England&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAvacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer<sup>\u00ae<\/sup> and pre|CISION\u2122 platforms, is pleased to announce that it has entered into a license agreement with Astrea Bioseparations (\u201cAstrea\u201d) for the use of the Affimer platform in affinity purification applications.\n<\/p>\n<p>\nAstrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences, the life sciences tools platform created by KKR, to build a leading position in next-generation bioprocessing for advanced therapies.\n<\/p>\n<p>\nFollowing Astrea\u2019s successful evaluation of Affimer reagents for affinity separation, the two companies have entered into a non-exclusive license agreement for the use of the Affimer technology in this field.\n<\/p>\n<p>\nThe agreement includes a \u00a30.5 million upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. It also provides Astrea with an option to convert the agreement into an exclusive license if certain commercial performance criteria are met over the next three years and subject to the payment of an additional undisclosed option exercise fee.\n<\/p>\n<p>\nAvacta will receive royalties on future sales of Astrea\u2019s purification products that contain Affimer reagents.\n<\/p>\n<p><b>Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented<\/b>: <i>\u201cI am delighted to have entered into this license agreement with Astrea following their evaluation of the Affimer platform. It is another strong endorsement of the Affimer technology as well as an important validation of the licensing business model driven by an active pipeline of ongoing, paid-for technology evaluations. <\/i><\/p>\n<p><i>Affimer reagents are ideal for affinity purification of biological products from complex mixtures because they are highly specific to the product and are robust enough to withstand the harsh cleaning conditions required for repeated use. <\/i><\/p>\n<p><i>Avacta\u2019s in-house focus is on the diagnostics applications of Affimer reagents and therefore this license agreement with Astrea allows the Group to commercialise the Affimer technology in a field of use where Affimer reagents perform extremely well but is now outside our main business focus.<\/i><\/p>\n<p><i>In addition, the Group has made excellent recent progress with its SARS-CoV-2 lateral flow rapid antigen test programme and we anticipate data from the first clinical trial soon. Our clinical evaluation of the BAMS\u2122 laboratory assay is ongoing at two UK clinical sites that Avacta has established and we have made significant commercial progress for all of our coronavirus testing solutions, establishing scalable routes to market for these products to meet the anticipated very high demand. I look forward to reporting on progress on all these fronts in the New Year and to a very exciting 2021 for the Group.\u201d<\/i><\/p>\n<p><b>Steve Burton, President of Astrea Bioseparations commented: <\/b><i>\u201cAffimer reagents are high-performance proteinaceous ligands that have been engineered for a wide range of applications as superior alternatives to antibody-based ligands. They can be used to selectively bind difficult targets, even where antibodies and aptamers have shown limitations. In combination with our proven Mimetic Ligand<sup>\u00ae<\/sup> chemical ligand libraries, the Affimer ligand platform significantly expands our capacity to discover, develop and deliver custom affinity adsorbents for purification of biotherapeutics and advanced therapies.\u201d<\/i><\/p>\n<p><i>This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596\/2014 (MAR)..<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201221005267\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201221005267\/en\/<\/a><\/span><\/p>\n<p><b>Zyme Communications<\/b> (Trade and Regional Media)<br \/>\n<br \/>Katie Odgaard<br \/>\n<br \/>Tel: +44 (0)7787 502 947<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:katie.odgaard@zymecommunications.com\">katie.odgaard@zymecommunications.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201221005267\/en\/848251\/3\/Avacta_%28CMYK%29_reg_LinkedIn_436x228pi.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Avacta Group plc Signs License Agreement With Astrea Bioseparations License for the use of the Affimer platform for affinity purification applications CAMBRIDGE, England &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211; Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer\u00ae and pre|CISION\u2122 platforms, is pleased to announce that it has entered into a license agreement with Astrea Bioseparations (\u201cAstrea\u201d) for the use of the Affimer platform in affinity purification applications. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences, the life sciences tools platform created by KKR, to build a leading position in next-generation bioprocessing for advanced therapies. Following Astrea\u2019s successful evaluation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avacta Group plc Signs License Agreement With Astrea Bioseparations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403346","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avacta Group plc Signs License Agreement With Astrea Bioseparations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avacta Group plc Signs License Agreement With Astrea Bioseparations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Avacta Group plc Signs License Agreement With Astrea Bioseparations License for the use of the Affimer platform for affinity purification applications CAMBRIDGE, England &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211; Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer\u00ae and pre|CISION\u2122 platforms, is pleased to announce that it has entered into a license agreement with Astrea Bioseparations (\u201cAstrea\u201d) for the use of the Affimer platform in affinity purification applications. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences, the life sciences tools platform created by KKR, to build a leading position in next-generation bioprocessing for advanced therapies. Following Astrea\u2019s successful evaluation &hellip; Continue reading &quot;Avacta Group plc Signs License Agreement With Astrea Bioseparations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T08:53:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avacta Group plc Signs License Agreement With Astrea Bioseparations\",\"datePublished\":\"2020-12-21T08:53:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/\"},\"wordCount\":619,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/\",\"name\":\"Avacta Group plc Signs License Agreement With Astrea Bioseparations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-21T08:53:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avacta Group plc Signs License Agreement With Astrea Bioseparations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avacta Group plc Signs License Agreement With Astrea Bioseparations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/","og_locale":"en_US","og_type":"article","og_title":"Avacta Group plc Signs License Agreement With Astrea Bioseparations - Market Newsdesk","og_description":"Avacta Group plc Signs License Agreement With Astrea Bioseparations License for the use of the Affimer platform for affinity purification applications CAMBRIDGE, England &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211; Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer\u00ae and pre|CISION\u2122 platforms, is pleased to announce that it has entered into a license agreement with Astrea Bioseparations (\u201cAstrea\u201d) for the use of the Affimer platform in affinity purification applications. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences, the life sciences tools platform created by KKR, to build a leading position in next-generation bioprocessing for advanced therapies. Following Astrea\u2019s successful evaluation &hellip; Continue reading \"Avacta Group plc Signs License Agreement With Astrea Bioseparations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T08:53:33+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avacta Group plc Signs License Agreement With Astrea Bioseparations","datePublished":"2020-12-21T08:53:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/"},"wordCount":619,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/","name":"Avacta Group plc Signs License Agreement With Astrea Bioseparations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-21T08:53:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201221005267r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avacta-group-plc-signs-license-agreement-with-astrea-bioseparations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avacta Group plc Signs License Agreement With Astrea Bioseparations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403346"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403346\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}